Inclusion Criteria:

- Subjects must have a histologically confirmed metastatic RCC with a clear cell
component

- Low or intermediate risk according to the Memorial Sloan Kettering Cancer Center
(MSKCC) prognostic risk classification.

- Measurable disease with at least one unidimensionally measurable lesion per RECIST
guidelines with modifications

- Adequate organ and hematological function as evidenced by laboratory studies
conducted at Screening.

- ECOG of 0 or 1

Exclusion Criteria:

Disease Related

- Known history of central nervous system metastases.

- Previous treatment (excluding surgery and palliative radiotherapy) for advanced or
metastatic renal cell carcinoma

- Focal radiation therapy for palliation of pain from bony metastases within 14 days of
randomization.

Medications

- Currently or previously treated with inhibitors of VEGF.

- Currently or previously treated with inhibitors of angiopoietin or Tie2.

- Currently or previously treated with bevacizumab.

General Medical

- Diagnosis of acute pancreatitis.

- Myocardial infarction, cerebrovascular accident, transient ischemic attack,
percutaneous transluminal coronary angioplasty/stent, congestive heart failure, grade
2 or greater peripheral vascular disease, arrhythmias not controlled by outpatient
medication, or unstable angina within 1 year prior to randomization

- Major surgery within 30 days before randomization or still recovering from prior
surgery

- Uncontrolled hypertension as defined as diastolic > 90 mmHg OR systolic >150 mmHg.
Anti-hypertensive medications are permitted.

Other

- Other investigational procedures are excluded

- Subject currently is enrolled in or has not yet completed at least 30 days since
ending other investigational device or drug study(s), or subject is receiving other
investigational agent(s)